Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage

• Published in: Pathology oncology research Vol. 26; no. 2; pp. 599 - 603
• Main Authors: Luo, Ping, Wu, Sanyun, Yu, Yalan, Ming, Xinliang, Li, Shuo, Zuo, Xuelan, Tu, Jiancheng
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.04.2020; Springer Nature B.V
• Subjects: alpha-Fetoproteins - metabolism; Biomarkers; Biomarkers, Tumor - analysis; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Hepatocellular - diagnosis; Diagnosis; Early Diagnosis; Hepatocellular carcinoma; Humans; Immunology; Liver cancer; Liver Neoplasms - diagnosis; Medical diagnosis; Medical screening; Morbidity; Oncology; Pathology; Review; Therapeutic applications; α-Fetoprotein; HCC; Biomarker; AFP-negative; Diagnose
• ISSN: 1219-4956; 1532-2807
• DOI: 10.1007/s12253-019-00585-5

Hepatocellular carcinoma (HCC) is one of the most malignant cancer with high morbidity and mortality which lead to a serious burden to society. AFP (alpha-fetoprotein) is the most widely used serum biomarker to detect HCC worldwide. However, no AFP elevation have been found in many HCC and AFP analysis can’t be used to screen HCC in these cases. Currently, many studies have been carried out to find reliable biomarker in diagnosing AFP-negative HCC. Such biomarker would help the diagnosis of AFP-negative HCC, ensuring the timely initiation of treatment. In this review, we highlight the important role of biomarkers that can differentiate AFP-negative HCCs, and discuss their potential clinical applications as biomarkers for the diagnosis of AFP-negative HCC.